Firefly Neuroscience, Inc.
AIFF · Price history
Price at last available close
$1.05
−$0.57 (-35.19%) 1M
2026-10-28
Tap or drag sideways to inspect a price. Use two fingers to compare automatically. Release to scroll. Use Shift + arrow keys to compare with a keyboard.
Company & revenue
About Firefly Neuroscience, Inc.
Primary reporting period: 2025-12-31 · Research updated Oct 13, 2026. A research update is not a new financial filing.
Who they are
Based in Toronto, Canada, Firefly Neuroscience, Inc. is a medical technology and artificial intelligence firm specializing in developing neuroscientific solutions. The company's primary goal is to enhance patient outcomes for individuals affected by mental illnesses and neurological disorders. Its flagship product, Brain Network Analytics, is a sophisticated software platform engineered to aid in the diagnosis and treatment of a diverse range of cognitive and psychiatric conditions.
How they make money
Firefly Neuroscience, Inc. generates revenue primarily through the development, marketing, and distribution of medical devices and AI-driven software platforms. These technologies provide clinicians with objective, high-resolution visualization and analysis of neuro-physiological data to assist in the evaluation of brain function.
Products & services
The company offers the Brain Network Analytics (BNA) platform, which utilizes artificial intelligence and large-scale electrophysiological data to provide objective assessments of brain health and function for clinical use.
Brands & revenue mix
The core AI-based software platform used for analyzing brain function.
Separate brand revenue is not available in this research.Source
Revenue share is not unit sales or a best-seller ranking. Parent brands and included sub-brands can overlap; do not add overlapping rows.
Product / operating segments
No reconciled product or operating-segment revenue breakdown is available for the current research period. Company-wide revenue remains separate from segment disclosure.
Geographic revenue
No reconciled geographic revenue breakdown was confirmed for the current research period.
Customer concentration
The company's revenue is derived from a limited number of clinical customers, and the loss of any significant customer could materially impact financial results as disclosed in the 2025 10-K.
Suppliers, materials & equipment
- Contract Manufacturers — The company relies on third-party contract manufacturers for the production of its medical device hardware components.Source
Competitors
- Neuro-diagnostic technology companies — Various companies providing EEG-based diagnostic tools and brain imaging software that compete for clinical adoption in the neuro-diagnostic market.Source
Strengths
Sources
Wall Street Score
Overall investment score · Quality, value, risk and opportunity
10
Poor
View category scores →
Company Quality
How good is the actual business—regardless of today’s stock price?
61
Fair
Financial Strength
70
Business Quality / Moat
75
Management
40
Growth Quality
82
Risk / Durability
10
Uses financial strength, moat, management, growth quality and durability. It excludes share price, P/E, market cap, intrinsic value and margin of safety.
Model Outlook
12-month model · What does the model think happens next?
Outperformance analysis is not currently available.
WSS View
The quick read
The overall Wall Street Score is low across its combined quality, valuation and risk inputs. This can reflect an expensive share price, business weaknesses, or both; check Company Quality and the category breakdown before drawing a conclusion.
A current Opportunity Score is not available.
The 12-month model outlook is not currently available.
- •Balance-sheet / debt profile scores strongly
- •Asset quality scores strongly
- •MAJOR RED FLAG: Reverse split proposed / authorized
- •CRITICAL: Going-concern warning
- •CRITICAL: Bankruptcy / liquidation risk
- •Debt service risk
- •Valuation is a weaker part of the current profile
Company-specific research
Questions worth answering for AIFF
These questions are generated from this company's current financial and score data so the page adds context instead of treating the headline score as a stand-alone conclusion.
- •Can AIFF maintain its current revenue growth rate and improve the amount of that revenue that turns into earnings and cash?
- •How long can AIFF fund negative free cash flow using its current cash position before it may need more debt or new shares?
- •How is AIFF likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
- •What specifically needs to improve for AIFF to reach sustainable profitability?
- •What future growth or profitability would be needed to justify AIFF's current valuation?
Essential Investment Snapshot
Wall Street Score
10
Market Cap
$16.5M
P/E Ratio
-2.4
EPS
$-0.64
52-Week High
$3.15
52-Week Low
$0.62
Beta
0.57
Shares Outstanding
13.5M
Total Revenue
$1.8M
Total Debt
$0
Dividend
No current dividend
Liquidation Value / Share
$1.09
Momentum & Volatility Signals
Two different market-behavior signals. Momentum measures direction and trend strength. Volatility measures how large and unstable the price moves are, regardless of direction.
Strong downward momentum
Elevated movement
A high momentum score means price has been trending upward with confirming short- and medium-term strength. A low score means downward or weakening momentum.
A high volatility score means larger, less stable price swings. It can happen while a stock is rising or falling, so high volatility is not automatically bullish or bearish.
Important: the volatility score above is based on realized price volatility. Implied volatility (IV) comes from options prices and represents the market's expected future movement. Wall Street Score will keep IV separate and will only display it when a verified options-chain feed is available.
Notices for AIFF
Detected from reported data — verify before acting.MAJOR RED FLAG: Reverse split proposed / authorized
A recent SEC filing discusses authorization, approval, or a proposal for a reverse stock split. This is treated as a major distress/listing-risk signal and caps Wall Street Score below 30 while pending.
Supporting filingCRITICAL: Going-concern warning
A recent SEC filing contains explicit going-concern language. Wall Street Score is capped at 15 until the distress condition is resolved in later filings.
Supporting filingCRITICAL: Bankruptcy / liquidation risk
A recent SEC filing contains bankruptcy/liquidation language. Wall Street Score is capped at 10.
Supporting filingDebt service risk
Interest coverage is low (~-54.1x). Earnings may be strained to cover interest expense.
Community Sentiment
0 active · 0 total callsNo personal call yet on AIFF.
Potential upside factors
- +Growth opportunities may come from revenue expansion, margin improvement, new products, market-share gains, and stronger cash flow.
- +Proprietary AI-driven BNA technology platform.
- +Extensive database of neuro-physiological data.
Potential downside factors
- −Key risks may include competition, margin pressure, debt levels, valuation risk, and changes in demand within the Software - Application industry.
- −History of operating losses and potential going concern issues.
- −Dependence on regulatory approvals for medical devices.
- −A recent SEC filing discusses authorization, approval, or a proposal for a reverse stock split. This is treated as a major distress/listing-risk signal and caps Wall Street Score below 30 while pending.
These research factors come from saved company research and financial data, not community votes. They are starting points to verify against filings, not buy or sell recommendations.
Create a free account to make a call.
Scores
Click any score for full breakdownWas this stock page easy to understand?
One click helps us improve the research experience. This is not tied to an investment decision.
Score Changes
5 historical score records availablePrevious Score
38
Sep 8, 2026
Change
-0.8
points
Current Score
37
Oct 1, 2026
Category Changes
AIFF decreased 0.8 points because Asset declined by 8.5 points.
Negative Contributors
- − Asset declined by 8.5 points
Projected Score
Projected Score
35
Projected Change
-1.6 points
Preliminary comparable-period financial changes suggest decline of approximately 1.6 points. This is a projected estimate, not the official WallStreetScore.
Price vs. Value
Valuation unavailableCurrent Price
$1.05
Model Intrinsic Value
—
Difference
—
Margin of Safety
—
Intrinsic value is not currently available for this stock, so valuation can't be calculated.
Financial Charts
Revenue
Additional Metrics
Operating Cash Flow
Total Debt
Total Assets
Net Margin %
Large reported revenue change: +957.4%
Revenue changed sharply from 2024 to 2025. This can reflect a real business change, acquisition, divestiture, discontinued operations, restatement, or reporting-basis change. Compare the underlying filing before treating it as normal growth or decline.
TTM may combine quarters from before and after the event, so its trend can also be distorted.
Free includes 3 annual periods plus available TTM; Premium includes up to 10 annual periods. History depends on available company filings. Swipe the table horizontally to see older periods. A dash means unavailable, not zero.
| Line Item | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Revenue | $1.8M | $1.1M | $108K | $498K | ···· | ···· | ···· |
| Cost of Revenue | $997K | $497K | $67K | $0.00 | ···· | ···· | ···· |
| Gross Profit | $802K | $645K | $41K | $498K | ···· | ···· | ···· |
| Research & Development | $1.8M | $1.5M | $2.0M | $741K | ···· | ···· | ···· |
| SG&A Expenses | $7.9M | $7.8M | $7.3M | $2.8M | ···· | ···· | ···· |
| Operating Expenses | $9.7M | $9.3M | $9.2M | $3.6M | ···· | ···· | ···· |
| EBITDA | -$8.9M | -$19.5M | -$10.3M | -$2.6M | ···· | ···· | ···· |
| Operating Income | -$8.9M | -$8.6M | -$9.2M | -$3.1M | ···· | ···· | ···· |
| Interest Expense | $29K | $159K | $69K | $18K | ···· | ···· | ···· |
| Income Before Tax | -$9.1M | -$19.9M | -$10.5M | -$2.6M | ···· | ···· | ···· |
| Income Tax Expense | $1K | $5K | $2K | $1K | ···· | ···· | ···· |
| Net Income | -$9.1M | -$19.9M | -$10.5M | -$2.6M | ···· | ···· | ···· |
| Basic EPS | $-0.21 | $-1.86 | $-1.60 | $-0.33 | ···· | ···· | ···· |
| Basic Shares | 20.58M | 13.20M | 6.55M | 7.87M | ···· | ···· | ···· |
| Diluted Shares | 20.58M | 13.50M | 6.55M | 7.87M | ···· | ···· | ···· |
Earnings Summary
Revenue
$514000
Estimate unavailable.
Revenue Beat/Miss
Not available (no estimate stored)
EPS
-$0.10
Estimate unavailable.
EPS Beat/Miss
Not available (no estimate stored)
Debt Change
Not available
Cash Change
+55.9%
Margin Change
+227.1 pp
Debt and cash show percentage changes versus the comparison period; margin shows the change in percentage points (pp). These are company-wide changes, not per-share amounts.
Financial Changes Since Prior Period
What Improved
- Margins expanded
- Cash position grew
Potential Score Impact
Positive indicators included revenue growth, cash levels, net income margin. Pressure indicators included EPS growth. These factors may support or pressure the Revenue, Management, Financial, and Debt categories; this summary does not claim that the stored scores changed.
Stored Earnings Analysis
Revenue increased 71.9%. EPS declined 31.1%. Cash increased 55.9%. Net income margin improved by 227.1 percentage points.
Earnings-Call Transcript
Earnings-call transcript analysis is not currently available.
These results may influence future scores when the next evaluation is completed.
Insider Activity
Guru / Smart Money
Guru Score
Smart Money
Number of Gurus
Total Guru Value
Avg Portfolio Weight
Largest Holder
Largest Holder %
New Positions
Increased Positions
Reduced Positions
Exited Positions
Net Guru Sentiment
Short Interest
Dividend History
Dividend data is not available yet. Missing data does not mean this company pays no dividend.
Conservative Projected Values
3 Years
$———.——
5 Years
$———.——
10 Years
$———.——
Conservative Projection Rate
——%
Conservative Projected Values — price projections derived from actual 10-year adjusted historical returns, conservatively adjusted and capped at 8% annually. These are distinct from the Outperformance Model Score and WallStreetScore.
Conservative Projected Values
Premium unlocks the 3-year, 5-year, and 10-year conservative projected values with full calculation breakdowns based on actual historical returns.
Start 7-Day Free TrialHistorical Outperformance Record
Premium includes stored forecasts and any available evaluated results. Completed results, win rates and calibrated probabilities are shown only when supported records exist; access does not create historical outcomes.
Start 7-Day Free TrialHistorical Trends
5 historical recordsHistorical Score Chart
3 of 5 records shownWall Street Score
Debt Score
Revenue Score
Asset Score
Capital Score
Management Score
Moat Score
Valuation Score
Buffett Score
Intrinsic Value
Value Reference
Margin of Safety %
Related Companies
Software - ApplicationNews
Firefly Neuroscience and Neurosigma Partner To Expand Non-Drug Pediatric ADHD Care
Firefly (NASDAQ: AIFF) and NeuroSigma Partner to Expand Access to First FDA-Cleared, Non-Drug Treatment for Pediatric ADHD
Firefly Neuroscience's Evoke™ Platform Selected to Bring Objective Brain-Function Insights to Radial's AI-Native Operating System for Brain Medicine
Firefly Neuroscience (NASDAQ:AIFF) vs. Pro Medicus (OTCMKTS:PMCUF) Head-To-Head Analysis
Rumor Mill · AIFF
Corporate developments & opportunities
No reviewed developments match this filter.
Evidence credibility is not a forecast of stock performance. Rumor Mill is separate from the WSS score.
Related Stock Research
Continue researching this company with related Wall Street Score rankings and investing guides.
Score Alerts
Premium unlocks alerts when a score rises, falls, or reaches your target price.
Start 7-Day Free TrialPortfolio Score
Premium unlocks portfolio scoring, strongest and weakest holdings, and overall margin of safety.
Start 7-Day Free Trial